Ming Yin
About Ming Yin
Ming Yin serves as the Vice President and Head of Biometrics at Bolt Biotherapeutics, Inc. since 2022, bringing extensive experience in biostatistics from previous roles at Acerta Pharma, Loxo Oncology, and Genentech.
Work at Bolt Biotherapeutics
Ming Yin serves as the Vice President and Head of Biometrics at Bolt Biotherapeutics, Inc. since 2022. In this role, he oversees the biometrics function, which includes statistical analysis and data management for clinical trials. His leadership is critical in advancing the company's biotherapeutic development initiatives. Bolt Biotherapeutics is located in Redwood City, California, where Yin contributes to the company's mission of developing innovative cancer therapies.
Education and Expertise
Ming Yin holds a Master's degree in Probability and Statistics from Peking University. He furthered his education by obtaining a Ph.D. in Statistics from the University of Florida. His academic background provides a strong foundation for his expertise in biostatistics and data analysis, essential for his roles in the pharmaceutical industry.
Background in Biostatistics
Prior to his current position, Ming Yin held several significant roles in biostatistics. He was the Director of Biostatistics at Acerta Pharma B.V., a member of the AstraZeneca Group, from 2016 to 2020. Following that, he served as the Executive Director and Head of Biostatistics at Loxo Oncology at Lilly from 2020 to 2022. His extensive experience in these roles has equipped him with a comprehensive understanding of statistical methodologies in drug development.
Career at Genentech
Ming Yin worked at Genentech as a Senior Statistical Scientist from 2004 to 2014. During his ten years at Genentech, he contributed to various projects that involved statistical analysis for clinical trials. His work in this prominent biotechnology company helped shape his career in biostatistics and provided valuable insights into the drug development process.